Status: Recruiting
Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC
Multicenter Phase 3 study of 177Lu-TLX250 in adult participants with CAIX-expressing advanced, relapsed or recurrent clear cell renal cell carcinoma (ccRCC). Part 1 will evaluate two dosing regimens to determine the recommended Phase 3 dose (RP3D). Part 2 will compare 177Lu-TLX250 with investigator's choice of monotherapy aligned with Australian standard-of-care.
Participants needed: 40
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Telix Pharmaceuticals (Innovations) Pty LimitedUpdated: Apr 1, 2026Locations: 5
Eligibility criteria
be aged ≥ 18 years. [+16]
visceral metastatic lesions that are ≥ 1 cm that have a CAIX TLR < 1; [+27]